Jacobio Pharmaceuticals Group Co., Ltd. has entered into agreements involving a capital increase and equity transfer related to its subsidiary, Jacoray Pharmaceutical Technology Co., Ltd. Following the transaction, Beijing Jacobio, an industry partner, and Oceanpine Capital will hold 80%, 10%, and 10% equity interests in Jacoray, respectively. As a result, Jacoray will no longer be a wholly-owned subsidiary of Beijing Jacobio. Proceeds from the transaction, after tax and expenses, are intended to support research and development, production, and commercialization of the company's Pan-KRAS inhibitor and other innovative oncology therapies.